Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
- Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease
- Marks latest step in Mission’s relationship with The Michael J. Fox Foundation (MJFF), after MJFF awarded Mission preclinical research grants in 2017 and 2021, and first with Parkinson’s UK
- Comes as promising early data from healthy volunteers show MTX325 has a good safety profile, pharmacokinetics and CNS penetration
Cambridge, UK – 02 July 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s, MTX325.
